Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1519-1538

  Schiffer, C A ^a   Anderson, K C ^a   Bennett, C L ^a   Bernstein, S ^a   Elting, L S ^a   Goldsmith, M ^a   Goldstein, M ^a   Hume, H ^a   McCullough, J J ^a   McIntyre, R E ^a   Powell, B L ^a   Rainey, J M ^a   Rowley, S D ^a   Rebulla, P ^a   Troner, M B ^a   Wagnon, A H ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RHESUS D ANTIGEN;

ADOLESCENT; ADULT; ALLOIMMUNIZATION; APHERESIS; ARTICLE; BLEEDING; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CLINICAL PRACTICE; CLINICAL TRIAL; FIBEROPTIC BRONCHOSCOPY; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HUMAN; INFANT; LEUKEMIA; LUMBAR PUNCTURE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOLOGY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0035282068     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1519     Document Type: Article

References (143)

1. The Canadian task force on the periodic health examination
2. Rules of evidence and clinical recommendations on the use of antithrombotic agents
3. Rules of evidence and clinical recommendations on the use of antithrombotic agents
4. Platelet production in the Old World - And the New
5. Preparation and storage of platelet concentrates. II. Storage and variables influence platelet viability and function
6. Optimum centrifugation conditions for the preparation of platelet and plasma products
7. Optimizing recovery of platelets in platelet rich plasma by the simplex strategy
8. Preparation and storage of platelet concentrates. I. Factors influencing the harvest of viable platelets from whole blood
9. A study of variables affecting the quality of platelets stored at "room temperature"
10. Hemostatic effectiveness of platelets stored at 22°C
11. Studies of platelet concentrates stored at 22°C and 4°C
12. Relative hemostatic effectiveness of human platelets stored at 4°C and 22°C
13. Viability and function of platelet concentrates stored in CPD-adenine (CPDA-1)
14. Platelet storage at 22°C: Effect of type of agitation on morphology, viability, and function in vitro
15. Improved storage of platelets for transfusion in a new container
16. Platelet storage for seven days in second generation CLXTM blood bags
17. Bacterial proliferation in platelet concentrates
18. Bacterial sepsis secondary to platelet transfusion: An adverse effect of extended storage at room temperature
19. Clinical evaluation of platelet concentrates stored for one to five days
20. International forum: Europe. Buffy-coat-derived platelet concentrates: Swedish experience
21. Platelet concentrates stored in plasma for 72 hours at 22°C prepared from buffy coats of citrate-phosphate-dextrose blood collected in a quadruple-bag saline-adenine-glucose-mannitol system
22. Platelet concentrates in an additive solution prepared from pooled buffy coats
23. Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium
24. A comparative analysis of different methods for routine blood component preparation
25. 51Cr
26. Quality and standardization in blood component preparation with an automated blood processing technique
27. Concentration of platelet units into small volumes
28. Reduction of the volume of stored platelet concentrates for use in neonatal patients
29. Platelet collection and transfusion using the Fenwal CS-3000 cell separator
30. Collection of platelets with a new cell separator and their storage in a citrate-plasticized container
31. Plateletpheresis with the COBE Spectra single needle access option
32. Description and use of the CS-3000 blood cell separator for single-donor platelet collection
33. Collection of platelets depleted of red and white cells with the "surge pump" adaptation of a blood cell separator
34. The surge technique: A method to increase purity of platelet concentrates obtained by centrifugal apheresis
35. Leukoreduced platelet apheresis production with a modified COBE spectra collection protocol
36. Efficacy of platelets collected by semi-continuous flow centrifugation (Haemonetics Model 30)
37. In vitro and in vivo comparison of single-donor platelets and multiple-donor pooled platelets transfusions in leukemic patients
38. Paired in vivo and in vitro comparison of apheresis and "recovered" platelet concentrates stored for five days
39. Storage of platelets collected by apheresis
40. Collection and transfusion of blood and blood components in the United States, 1994
41. A comparison of platelets prepared by the Haemonetics model 30 and multiunit bag plateletpheresis
42. Leukocyte reduction and UV-B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusion
43. A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets
44. The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets
45. Pooled platelet concentrates: Maybe not fancy, but fiscally sound and effective
46. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections
47. Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients
48. Effect of platelet transfusion on hemorrhage in patients with acute leukemia
49. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study
50. Indications for platelet transfusion in children with acute leukemia
51. The quantitative relation between platelet counts and hemorrhage in patients with acute leukemia
52. Thrombocytopenia: Mechanisms and management of defects in platelet production
53. Platelet transfusion therapy. National Institutes of Health Consensus Conference
54. Consensus conference on platelet transfusion. Royal College of Physicians of Edinburgh, 27- 28 November 1997
55. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia
56. Use of platelets and other transfusion products in patients with malignancy
57. Prophylactic platelet transfusion in acute leukaemia
58. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μ
59. The Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia
60. 9/L, trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia
61. Estimation of the lower limits of manual and automated platelet counting
62. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution
63. Lowering the prophylactic platelet transfusion (ProPltTx) trigger: A prospective analysis
64. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation
65. Acute bleeding after bone marrow transplantation (BMT): Incidence and effect on survival - A quantitative analysis in 1,402 patients
66. A prospective randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
67. Reinventing bone marrow transplantation: Reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-vs-malignancy
68. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia
69. Incidence of hemorrhagic complications in patients with cancer
70. Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors
71. Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer
72. Conservative management of chemotherapy-induced thrombocytopenia in women with gynecologic cancers
73. Risk and outcomes of chemotherapy (chemo)-induced thrombocytopenia (TCP) in solid tumor patients
74. Surgery in acute leukemia: A review of 167 operations in thrombocytopenic patients
75. Spinal subdural hematomas complicating lumbar puncture
76. Radicular vessels are the most probable source of needle induced blood in lumbar puncture
77. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thromb-ocytopenia
78. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities
79. Thrombocytopenia and gastrointestinal hemorrhage in the cancer patient: Prevalence of unmasked lesions
80. Complications of fiberoptic bronchoscopy in thrombocytopenic patients
81. Transbronchial biopsy in the thrombocytopenic patient
82. Bronchoscopy with transbronchial biopsies: Measurement of bleeding volume and evaluation of the predictive value of coagulation tests
83. The safety of dental extractions in patients with hematologic malignancies
84. Dental extractions in patients with acute nonlymphocytic leukemia
85. Central venous catheter placement in patients with disorders of hemostasis
86. Percutaneous isoelastic catheter insertion in patients with thrombocytopenia
87. Patients with thrombocytopenia: Outcome of radiologic placement of central venous access devices
88. The value of 10-minute post transfusion platelet counts
89. Erythrocyte antigens on human platelets. Absence of the Rhesus, Duffy, Kell, Kidd and Lutheran antigens
90. Rh incompatible platelet transfusion: Risks and consequences of sensitizing immunosuppressed patients
91. Transfusion of Rh-incompatible blood components to cancer patients
92. Alloimmunization to D antigen and HLA in D-negative immunosuppressed oncology patients
93. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients
94. Intravenous anti-D gamma-globulin for the prevention of Rhesus isoimmunization caused by platelet transfusions in patients with malignant disease
95. A dose of 100 IU intravenous anti-D gammaglobulin is effective for the prevention of RhD immunisation after RhD-incompatible single donor platelet transfusion
96. Recommendations for the use of anti-D immunoglobulin for Rh prophylaxis
97. Recommendations for the use of anti-D immunoglobulin
98. Alloimmunization following platelet transfusion: The absence of a dose response relationship
99. Long-term follow-up of patients with leukemia receiving platelet transfusions: Identification of a large group of patients who do not become alloimmunized
100. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients
101. Transplantation antigen activity of human blood platelets
102. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension
103. Approaches to preventing or reversing platelet alloimmunization using animal models
104. Transfusion-induced alloimmunization and immunosuppression and the effects of leukocyte depletion
105. Ultraviolet irradiation of blood prevents transfusion induced sensitization and marrow graft rejection in dogs
106. The role of UV radiation in the prevention of human leukocyte antigen alloimmunization
107. Platelet concentrates irradiated with ultraviolet light retain satisfactory in vitro storage characteristics and in vivo survival
108. A randomized trial of leukocyte depleted platelet transfusion to modify alloimmunization in patients with leukemia
109. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components
110. The use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: A prospective, randomized trial
111. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components: A randomized trial
112. Prevention of refractoriness and HLA-alloimmunization using filtered blood products
113. Bedside filtration of blood products in the prevention of HLA alloimmunization: A prospective randomized study
114. Use of leucocyte-poor blood components and HLA-matched-platelet donors to prevent HLA alloimmunization
115. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: A randomized prospective study
116. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study
117. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration
118. Effective prophylaxis against platelet refractoriness in multitransfused patients by the use of leukocyte-free blood components
119. Prevention of alloimmunization against platelets
120. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions
121. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy
122. White cell reduction in platelet concentrates and packed red cells by filtration: A multicenter clinical trial
123. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions
124. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer
125. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients
126. The role of plasma from platelet concentrates in transfusion reactions
127. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
128. The collection of platelets by apheresis procedures
129. ABO compatibility can influence the results of platelet transfusion: Results of a randomized trial
130. Management of alloimmunized, refractory patients in need of platelet transfusions
131. Platelet transfusion therapy for alloimmunized patients: Selective mismatching for HLA B 12, an antigen with variable expression on platelets
132. Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion
133. The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients
134. Selection of histocompatible apheresis platelet donors by crossmatching random donor platelet concentrates
135. A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients
136. Temporary suppression of circulating antiplatelet alloantibodies by the massive infusion of fresh, stored, or lyophilized platelets
137. High dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients
138. Intravenous gammaglobulin for patients alloimmunized to random donor platelet transfusion
139. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients
140. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients
141. Plasma exchange for platelet alloimmunization